Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.Potential first-in-class oral prolonged-release formulation of ketamine, KET01,
Toronto, Ontario (Newsfile Corp. - March 22, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company, researching, developing and delivering
Awakn Life Sciences Appoints Kevin Lorenz as U S Head of Commercial Development streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the psychedelics space, composed of key thought.